Tag Archives: £ 12

Pargesa: Joint press release with Parjointco Switzerland SA | Instant News

Merger payouts are based on exchange ratios that are identical to public exchange offerings

Under the terms of the merger agreement, Pargesa’s minority shareholders will receive, for each of their Pargesa shareholder shares, a promissory note that awards them a value of 0.93 shares of Groupe Bruxelles Lambert (GBL) on 6 July 2020 or (if this amount is fixed). lower) at the time of merger registration in the Geneva commercial register. The share ratio of 0.93 GBL is identical to the exchange ratio offered in the public exchange offering to public shareholders of Pargesa, which was launched by Parjointco Switzerland in April and completed in July 2020. Parjointco Swiss board of directors will decide whether the promissory notes will be redeemed in cash or through delivery of GBL shares and will announce this by 23 November 2020.

About Parjointco

Parjointco Switzerland SA is a wholly owned subsidiary of Parjointco NV, an investment holding company created in 1990 by the Canadian Power Corporation group (controlled by the Desmarais family) and the Belgian Frère group. Under an initial agreement signed in 1990 by two family-owned groups, Parjointco NV is controlled by a group consisting of the Desmarais and Frère groups, which act collectively and on an equal basis. The last preliminary agreement was extended in 2012 to 31 December 2029, with conditions for possible further extensions.

About Pargesa

Pargesa Holding SA (Pargesa) is the holding company of the Pargesa Group. Leveraging on the support and stability of a partnership created in 1990 between two controlling shareholders (the Power Corporation group in Canada and the Frère group in Belgium), the Pargesa Group aims to create long-term value for the benefit of all its shareholders. , by building a portfolio of share ownership in companies that are market leaders in various industrial and service sectors, and acting as professional shareholders. Currently, the Pargesa Group portfolio is held through Pargesa’s subsidiary, Groupe Bruxelles Lambert (GBL). Pargesa is listed on the SIX Swiss Exchange (Ticker: PARG; ISIN: CH0021783391). The Pargesa website can be found at the address https://www.pargesa.ch/en/.

About Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (GBL) is an established investment holding company, with more than sixty years of being listed on the stock exchange. GBL is a leading investor in Europe, with a focus on long-term value creation and relying on a stable and supportive family shareholder base. GBL strives to maintain a diversified, high-quality portfolio of global companies, all leaders in their sector, with which GBL can contribute to value creation by being an active professional investor. GBL strives to provide attractive returns to its shareholders through a combination of sustainable dividends and growth in net asset value. GBL is listed on the Euronext Brussels stock exchange (Ticker: GBL BB, ISIN: BE0003797140) and is part of the BEL20 index. The GBL site can be seen at the address https://www.gbl.be/en/.


image source


12 October 2020 ASX Code: MXC

MGC Pharma shipped the first high THC formulation direct to

patients in Brazil through the ONIX online platform

Main Highlights:

  • MGC Pharma completes initial delivery of its Mercury Pharma line, which includes high THC products, direct to patients in Brazil through a supply and distribution agreement with ONIX
  • A major operational and commercial achievement as MGC Pharma is now the first company globally to ever supply high THC formulations directly to patients in Brazil under the country’s Compassionate Use Program.
  • Brazil is a market of strategic importance with a population of over 210 million1 people and pharmaceutical market value of ~ A $ 24 billion1 year
  • Potential to immediately develop new sales of materials and cash flow channels – new patients registering daily in Brazil for MGC Pharma products within weeks of first successful delivery
  • ONIX is actively recruiting doctors in Brazil and aims to have more than 1,000 doctors with the ability to prescribe cannabinoid products with mid-2021 – significantly broadens the market opportunities for MGC Pharma to supply its formulations

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC Pharma’ or ‘Company’), a European based biopharma company that specializes in production and development phytocannabinoid derivativespharmaceuticals, is pleased to announce that it has completed the first shipment of its Pharmaceutical Mercury line which includes a high THC ratio product direct to patients in Brazil through binding supply and distribution agreements with Based in BrazilONIX Empreendimentos e Participações (‘ONIX’), (see ASX release March 3, 2020).

In a major operational milestone, MGC Pharma has become the first company globally to deliver high THC formulations directly to a patient’s door in Brazil, without the need to visit a pharmacy.

MGC Pharma has delivered Mercury Pharma (MP) branded products directly to patients according to the Brazilian Compassion Use Program after receiving the patient prescription given by the ONIX referral doctor. ONIX currently has more than 100 referral doctors in Brazil who can prescribe cannabinoid products under its Compassion Use Program and aims to have more than 300 referral doctors by the end of calendar 2020 and more than 1,000 by mid-2021. A complete line of Mercury Pharmaceuticals is now available. in Brazil which, based on the years experience of the Company’s medical team, covers a product range from pure CBD (MP100) through different ratios (1:30, 1: 1, 7: 1, 15: 1) to pure THC product MP252.

Brazil – Access to Large Target Markets Underway for MGC Pharma

The existing pharmaceutical drug market in Brazil represents a geography of strategic importance for MGC Pharmacy as Brazil has a population of more than 210 million people1. The National Health Expenditure in Brazil is estimated at A $ 267b1 with total expenditures on drugs estimated at A $ 24 billion1 every year. According to Interfarma (Pharmaceutical Research Industry Association), the Brazilian pharmaceutical market is expected to grow from A $ 59.9 billion in 2019 to A $ 66 billion in 2023.3 , through sales of approximately 238 million units3.

  1. Prohibition Partners, LATAM Cannabis Report, 2018
  2. View the Mercury Pharma Brochure via the Company’s website
  3. Interfarma 2019 Guide



In addition, there are 10,000 patients in Brazil who are currently registered with the Brazilian local authority, ANVISA, to receive cannabinoid products directly who are suffering from various medical conditions. Only 350 doctors out of more than 500,000 doctors across Brazil are currently authorized to prescribe cannabinoid products. This is expected to change due to the number of initiatives used by ONIX.


ONIX is a company based in Brazil that helps companies doing business in the region. It develops its business under the ONIXCANN brand and is a well-established distributor of phytocannabinoid-based products in Brazil that connects doctors and patients. ONIXCANN has an innovative digital and telemedicine platform called CANTERAMED which connects potential patients with relevant medical professionals. CANTERAMED is a complete digital wellness platform that facilitates safe and legal access to phytocannabinoid products and to guide doctors and patients about available treatments.

ONIX has established a partnership with one of the major Universities in Brazil, Anima Educação, and has developed a post-graduation course consisting of 12 nano degree courses of 30 hours each designed to train experienced doctors on CBD and THC products and authorize them to prescribe cannabinoid products.

ONIX has launched the second generation of CANTERAMED platform to help doctors better serve their patients. The CANTERAMED platform has facilitated doctors’ practice with its protocol for using MGC Pharma products and registering treatment results. CANTERAMED includes a telemedicine platform that connects patients with trained doctors to prescribe MGC Pharma products.

ONIX is currently also visiting doctors with a traditional pharmaceutical model who educates doctors about products and aims to have more than 1,000 doctors with the ability to prescribe cannabinoid products to patients by mid-2021.

This initiative is expected to continue to drive market awareness and penetration of cannabinoid products for eligible patients in Brazil.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, comments: “I am very pleased to announce that we have successfully shipped our Mercury Pharma THC product range to Brazil. This is a great achievement as no other company has delivered high THC formulations directly to patients in Brazil before. We have worked closely with our Brazilian partner ONIX and remain confident that Brazil will become a very large strategic and commercially important region for us in the future. Feedback to date from patients in Brazil has been very positive and we see a rapidly increasing demand for our Mercury Pharmaceutical products. “

Marcelo Galvão, Founder of ONIX, comments: “We are very pleased to announce this. It has always been an important part of our strategy to bring high THC products to Brazil. There are more than 30,000 patients currently using homemade oils in Brazil and these patients are in desperate need of a quality product as we do now. take it with the Mercury Pharma Line. ”


Authorized for release by the Board, for more information please contact:

PR / IR advisor – Media & Capital Partners

MGC Pharmaceuticals Ltd.

Melissa Hamilton (PR) +61 417 750274

Roby Summer

Rod Hinchcliffe (IR) +61412277377

CEO & Managing Director

[email protected]

+61 8 6382 3390

[email protected]

[email protected]



About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based bio-pharmaceutical company that develops and supplies affordable standard phytocannabinoid-derived medicines to patients globally. The Company’s founders are key figures in the global medical cannabis industry and its core business strategy is to develop and supply high quality phytocannabinoid-derived pharmaceuticals for the growing demand in the medical market in Europe, North America and Australasia. MGC Pharma has a strong product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the path of development.

Using the ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academics to optimize the cultivation and development of targeted phytocannabinoid-derived medicinal products prior to production in the Company’s EU-GMP Certified manufacturing facilities.

MGC Pharma has a number of research collaborations with world-renowned academic institutions, and includes recent research highlighting the positive impact of using a specific phytocannabinoid formulation developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and thus far therapeutically resistant primary brain tumor.

MGC Pharma has a growing patient base in Australia, UK, Brazil and Ireland and has a global distribution footprint through an extensive network of commercial partners which means it is ready to supply the global market.

Follow us through our social media channels



This is an excerpt from the original content. To continue reading, access the original document here.


MGC Pharmaceuticals Ltd. publish this content on 11 October 2020 and take full responsibility for the information contained therein. Distributed by the Public, unedited and unaltered, at October 11 2020 21:54:08 UTC


image source

Reporters about hunger strike lost £ 12: Protest for editor-in-chief Jang / Geo | Instant News

LAHORE: Veteran journalist Azhar Munir has been on a hunger strike over the past 22 days for Jang’s release / News / Geo Editor in Chief Mir Shakilur Rehman has suffered from deteriorating health because he has lost quite a lot of weight over the past three weeks.

Azhar, 65, who has experienced weakness, lack of sleep and difficulty walking and standing over the past few days, has lost about 12 pounds (5.5 kg). Speaking with The News, he said one of his friends took him to a medical shop to measure a body weight that was more than 12 pounds less than normal before starting a hunger strike. But, Azhar said he was excited and felt himself stable. But his colleagues worried his weakness could make him vulnerable to other infections. His friends expressed concern about his life because he had been a smoker for nearly five decades and his lungs were also weak.

In addition, during the last few days he also suffered from indigestion occasionally when he had to eat after a long period of starvation. So far he has struggled alone sitting on a rug on a path outside the Lahore Press Club despite threats and insults from various places. Azhar said he respected and praised those who supported him by visiting his camp where he had sat on the rug for the past 22 days. He said when Mir Shakilur Rehman was arrested, it was clear that NAB violated its own law which said no one could be arrested during the verification stage. “I plan to invite reporters who look alike to go on a hunger strike. But there are some lobbies that praise the NAB’s actions. There was an incident that served as a catalyst for my desire to protest the arrest, “he said.

“The lobby issued a strong verbal threat to break the legs of anyone who went on strike to support the editor in chief. I knew the threat was directed at me. Then I decided to test the guts of this lobby, I declared my attack, challenging the bullies to hurt me, “he said.

Azhar Munir, a lifelong member of the Lahore Press Club, told The News that he had written his will, leaving all his movable and immovable property to the Lahore Press Club. “I legalized my will three to four years ago and told president Shahbaz Mian about it. When this hunger strike is over, I will also legalize the procedure and nominate authorized people to monitor my assets after my death, including land, cash, bonds and royalties from the book, “he said.

So far Azhar Munir has refused all requests to stop his strike, from the imprisoned editorial, friend and family of the chief editor. He stressed that he was there for reasons of democratic freedom for his calling of conscience. He said, “If the editor in chief releases his fair journalism policy, he will be released. It is time to support Mir Shakil-ur-Rahman before the government increases pressure on him. “


image source